Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
复制标题
恩卡尼、氟卡尼、丙咪嗪和莫雷西嗪对急性心肌梗死后一年内室性心律失常的影响：CAPS。
DOI：
10.1016/0002-9149(88)90754-0
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
CardiacArrhythmiaPilotStudy(CAPS)Investigators
中科院分区：
文献类型：
--
作者：
CardiacArrhythmiaPilotStudy(CAPS)Investigators
国家心脏、肺和血液研究所启动了心律失常先导研究（CAPS），以评估急性心肌梗死后抑制室性心律失常的可行性。10个中心纳入了502例年龄小于75岁的患者，24小时心电图记录中每小时心室过早复合物（VPC）大于或等于10个，左心室射血分数大于20%。患者在急性心肌梗死后6至60天入组，随机接受2种药物的5个治疗方案中的1个，包括恩卡因胺、氟卡因胺、丙咪嗪、莫西嗪或安慰剂。在双盲药物和剂量选择阶段，研究人员被允许改变药物或剂量，以达到大于或等于70%的VPC频率抑制和大于90%的VPC运行抑制（分配给安慰剂的患者除外，他们继续接受安慰剂）。随机分组后对患者进行了一年的随访。5个治疗组患者在年龄、性别、临床特征、VPC频次、左室射血分数及伴随药物治疗等方面相似。作为首发药物，恩卡因胺和氟卡因胺的有效率分别为79%和83%，高于丙咪嗪的52%、莫西嗪的66%和安慰剂的37%。对丙咪嗪或莫西嗪无效的患者，恩卡因胺和氟卡因胺也有很高的有效率，分别为68%和69%。Encainide、flecainide和moricizine耐受性良好。这3种药物的不良反应发生率不超过6%，与安慰剂相似。超过70%的患者在随访阶段开始使用encainide、flecainide或moricizine，直到研究结束。（摘要删节250字）
The National Heart, Lung, and Blood Institute initiated the Cardiac Arrhythmia Pilot Study (CAPS) to evaluate the feasibility of suppressing ventricular arrhythmias after acute myocardial infarction. Ten centers enrolled 502 patients younger than 75 years of age with greater than or equal to 10 ventricular premature complexes (VPC) per hour in a 24-hour electrocardiographic recording and a left ventricular ejection fraction greater than 20%. Patients were enrolled 6 to 60 days after acute myocardial infarction and randomized to 1 of 5 treatment tracks with 2 drugs that included encainide, flecainide, imipramine, moricizine or placebo. During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it. Patients were followed for a year after randomization. Patients in the 5 treatment arms were similar in age, sex, clinical characteristics, VPC frequency, left ventricular ejection fraction and concomitant drug treatment. As first drugs, encainide and flecainide had higher efficacy rates, 79% and 83%, respectively, than imipramine, 52%, moricizine, 66%, or placebo, 37%. Encainide and flecainide also had high efficacy rates, 68% and 69%, in patients who failed imipramine or moricizine. Encainide, flecainide and moricizine were well tolerated. These 3 drugs had intolerable adverse effect rates of 6% or less, i.e., similar to placebo. More than 70T of the patients who started the follow-up phase on encainide, flecainide or moricizine remained on these drugs to the end of the study.(ABSTRACT TRUNCATED AT 250 WORDS)
登录
查看更多内容
急性心肌梗死患者和恢复期患者静脉注射和口服托卡尼可预防室性快速心律失常。
影响因子：
4.8
作者：
L. Rydén;K. Arnman;T. Conradson;S. Hofvendahl;O. Mortensen;P. Smedgård
通讯作者：
P. Smedgård
氟卡尼与奎尼丁：多中心试验的结果。
DOI：
10.1016/0002-9149(84)90505-8
发表时间：
1984
期刊：
The American journal of cardiology
影响因子：
--
作者：
M. Hodges;D. Salerno;G. Granrud
通讯作者：
G. Granrud
急性心肌梗死住院晚期动态心电图记录检测到的室性心动过速（三种或更多复合波）的患病率、特征和意义。
影响因子：
2.8
作者：
J. Bigger;J. Bigger;F. M. Weld;F. M. Weld;L. Rolnitzky;L. Rolnitzky
通讯作者：
L. Rolnitzky
按室性心律失常类型进行分类可预测氟卡尼引起的不良心脏事件的频率。
影响因子：
24
作者：
J. Morganroth;J. Anderson;G. Gentzkow
通讯作者：
G. Gentzkow
信：术后免疫抑制。
DOI：
--
发表时间：
1974
期刊：
影响因子：
--
作者：
Parker Je
通讯作者：
Parker Je